 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Nausea and Vomiting
|
|
Ginger Supplements Reduce Chemotherapy-induced Nausea (5/20/2009)
Researchers from the University of Rochester-affiliated Community Clinical Oncology Program (CCOP) have reported that use of ginger supplements in combination with conventional antinausea drugs reduces chemotherapy-induced nausea to a greater extent than antinausea drugs alone. The details of this study will be presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando Florida, May 29-June.
Rezonic™ Enhances Effects of Zofran® and Dexamethasone for Prevention of Chemotherapy-induced Nausea and Vomiting (5/15/2009)
Researchers involved in an international randomized study have reported that cancer patients receiving Rezonic™ (casopitant) in addition to Zofran® (ondansetron) and dexamethasone have better control of chemotherapy-induced nausea and vomiting (CINV) than patients receiving only Zofran and dexamethasone. The details of this study appeared in an early online publication on May 11, 2009 in Lancet Oncology.
Acupressure Wristbands Relieve Nausea from Radiation Therapy (4/16/2009)
Researchers from the University of Rochester have reported that acupressure wristbands can reduce nausea among cancer patients receiving radiation therapy. The details of this study appeared in an early online publication in the Journal of Pain and Symptom Management on March 28, 2009.
Aloxi® Superior to Kytril® for Delayed Nausea and Vomiting Due to Chemotherapy (2/24/2009)
Researchers from Japan have reported that the combination of Aloxi® (palonosetron) and dexamethasone was as effective as Kytril® (granisetron) and dexamethasone for prevention of acute chemotherapy-induced nausea and vomiting (CINC) but was superior for prevention of delayed CINC. The details of this study appeared in the February 2009 issue of Lancet Oncology.
Physicians and Nurses Underestimate the Incidence of Delayed Chemotherapy-Induced Nausea and Vomiting (5/13/2004)
Researchers from 14 medical practices in Denmark, France, Italy, Germany, the UK, and the US have reported that physicians and nurses underestimate the incidence of delayed, chemotherapy-induced nausea and vomiting. This prospective study was supported by Merck and Company and was published in the May 15, 2004 issue of
Cancer.
Aloxi® Injection Incorporated into NCCN® antiemetic guidelines (3/30/2004)
MGI PHARMA, INC. announced today that Aloxi™ (palonosetron hydrochloride) injection has been incorporated into the 2004 National Comprehensive Cancer Network® (NCCN®) antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately and highly emetogenic chemotherapy. The 2004 guidelines will be made available on the NCCN Web site in the coming weeks.
Aloxi® Approved for Acute and Delayed Nausea and Vomiting (3/8/2004)
On July 25, 2003, the Food and Drug Association approved Aloxi® (palonosetron), for the prevention of:
Aprepitant (Emend®) Decreases Nausea and Vomiting Due to Cisplatin-Based Chemotherapy (11/24/2003)
Two randomized clinical trials published in the November 15, 2003 issue of the
Journal of Clinical Oncology demonstrated that the addition of Emend® to a standard anti-emetic regimen of ondansetron (Zofran®) and dexamethasone significantly reduced the incidence of cisplatin-induced nausea and vomiting.
1,2 These two randomized clinical trials were the basis for FDA approval of Emend®.
National Comprehensive Cancer Network Update on Anemia Includes Use of Aranesp® (11/5/2003)
The National Comprehensive Cancer Network’s (NCCN) updated clinical guidelines for the treatment and management of anemia, related to cancer and cancer therapy, recommend the use of Aranesp® (darbepoetin) or Procrit® (epoetin alfa).
|
|
Patient Home
